当前位置: 首页 >> 检索结果
1701. Regulatory T-cell therapy in Crohn's disease: challenges and advances.
作者: Jennie N Clough.;Omer S Omer.;Scott Tasker.;Graham M Lord.;Peter M Irving.
来源: Gut. 2020年69卷5期942-952页
The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn's disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn's disease.
1702. MiR130b from Schlafen4+ MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer.
作者: Lin Ding.;Qian Li.;Jayati Chakrabarti.;Andres Munoz.;Emmanuelle Faure-Kumar.;Ramon Ocadiz-Ruiz.;Nataliya Razumilava.;Guiying Zhang.;Michael H Hayes.;Ricky A Sontz.;Zoe Elena Mendoza.;Swapna Mahurkar.;Joel K Greenson.;Guillermo Perez-Perez.;Nguyen Thi Hong Hanh.;Yana Zavros.;Linda C Samuelson.;Dimitrios Iliopoulos.;Juanita L Merchant.
来源: Gut. 2020年69卷10期1750-1761页
The myeloid differentiation factor Schlafen4 (Slfn4) marks a subset of myeloid-derived suppressor cells (MDSCs) in the stomach during Helicobacter-induced spasmolytic polypeptide-expressing metaplasia (SPEM).
1705. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication.
作者: Joseph J Y Sung.;Olabisi Oluwabukola Coker.;Eagle Chu.;Chun Ho Szeto.;Simson Tsz Yat Luk.;Harry Cheuk Hay Lau.;Jun Yu.
来源: Gut. 2020年69卷9期1572-1580页
Helicobacter pylori is associated with gastric inflammation, precancerous gastric atrophy (GA) and intestinal metaplasia (IM). We aimed to identify microbes that are associated with progressive inflammation, GA and IM 1 year after H. pylori eradication.
1706. Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
作者: Loris Pironi.;Ezra Steiger.;Francisca Joly.;Geert J A Wanten.;Cecile Chambrier.;Umberto Aimasso.;Anna Simona Sasdelli.;Kinga Szczepanek.;Amelia Jukes.;Miriam Theilla.;Marek Kunecki.;Joanne Daniels.;Mireille J Serlie.;Sheldon C Cooper.;Florian Poullenot.;Henrik Højgaard Rasmussen.;Charlene W Compher.;Adriana Crivelli.;Sarah-Jane Hughes.;Lidia Santarpia.;Francesco William Guglielmi.;Nada Rotovnik Kozjek.;Lars Ellegard.;Stéphane M Schneider.;Przemysław Matras.;Alastair Forbes.;Nicola Wyer.;Anna Zmarzly.;Marina Taus.;Margie O'Callaghan.;Emma Osland.;Ronan Thibault.;Cristina Cuerda.;Lynn Jones.;Brooke Chapman.;Peter Sahin.;Núria M Virgili.;Andre Dong Won Lee.;Paolo Orlandoni.;Konrad Matysiak.;Simona Di Caro.;Maryana Doitchinova-Simeonova.;Luisa Masconale.;Corrado Spaggiari.;Carmen Garde.;Aurora E Serralde-Zúñiga.;Gabriel Olveira.;Zeljko Krznaric.;Estrella Petrina Jáuregui.;Ana Zugasti Murillo.;José P Suárez-Llanos.;Elena Nardi.;André Van Gossum.;Simon Lal.
来源: Gut. 2020年69卷10期1787-1795页
No marker to categorise the severity of chronic intestinal failure (CIF) has been developed. A 1-year international survey was carried out to investigate whether the European Society for Clinical Nutrition and Metabolism clinical classification of CIF, based on the type and volume of the intravenous supplementation (IVS), could be an indicator of CIF severity.
1707. Longitudinal metabolic and gut bacterial profiling of pregnant women with previous bariatric surgery.
作者: Kiana Ashley West.;Chidimma Kanu.;Tanya Maric.;Julie Anne Kathryn McDonald.;Jeremy K Nicholson.;Jia V Li.;Mark R Johnson.;Elaine Holmes.;Makrina D Savvidou.
来源: Gut. 2020年69卷8期1452-1459页
Due to the global increase in obesity rates and success of bariatric surgery in weight reduction, an increasing number of women now present pregnant with a previous bariatric procedure. This study investigates the extent of bariatric-associated metabolic and gut microbial alterations during pregnancy and their impact on fetal development.
1709. Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolome profiles.
作者: Pande Putu Erawijantari.;Sayaka Mizutani.;Hirotsugu Shiroma.;Satoshi Shiba.;Takeshi Nakajima.;Taku Sakamoto.;Yutaka Saito.;Shinji Fukuda.;Shinichi Yachida.;Takuji Yamada.
来源: Gut. 2020年69卷8期1404-1415页
Recent evidence points to the gut microbiome's involvement in postoperative outcomes, including after gastrectomy. Here, we investigated the influence of gastrectomy for gastric cancer on the gut microbiome and metabolome, and how it related to postgastrectomy conditions.
1710. Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study.
作者: Amanda J Cross.;Emma C Robbins.;Kevin Pack.;Iain Stenson.;Paula L Kirby.;Bhavita Patel.;Matthew D Rutter.;Andrew M Veitch.;Brian P Saunders.;Stephen W Duffy.;Kate Wooldrage.
来源: Gut. 2020年69卷9期1645-1658页
Postpolypectomy colonoscopy surveillance aims to prevent colorectal cancer (CRC). The 2002 UK surveillance guidelines define low-risk, intermediate-risk and high-risk groups, recommending different strategies for each. Evidence supporting the guidelines is limited. We examined CRC incidence and effects of surveillance on incidence among each risk group.
1712. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations.
作者: Cheuk-Chun Szeto.;Kentaro Sugano.;Ji-Guang Wang.;Kazuma Fujimoto.;Samuel Whittle.;Gopesh K Modi.;Chen-Huen Chen.;Jeong-Bae Park.;Lai-Shan Tam.;Kriengsak Vareesangthip.;Kelvin K F Tsoi.;Francis K L Chan.
来源: Gut. 2020年69卷4期617-629页
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed medications, but they are associated with a number of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complications.
1713. DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia.
作者: Vaidehi Krishnan.;Debbie Xiu En Lim.;Phuong Mai Hoang.;Supriya Srivastava.;Junichi Matsuo.;Kie Kyon Huang.;Feng Zhu.;Khek Yu Ho.;Jimmy Bok Yan So.;Christopher Khor.;Stephen Tsao.;Ming Teh.;Kwong Ming Fock.;Tiing Leong Ang.;Anand D Jeyasekharan.;Patrick Tan.;Khay-Guan Yeoh.;Yoshiaki Ito.
来源: Gut. 2020年69卷10期1738-1749页
Intestinal metaplasia (IM) is a premalignant stage that poses a greater risk for subsequent gastric cancer (GC). However, factors regulating IM to GC progression remain unclear. Previously, activated DNA damage response (DDR) signalling factors were shown to engage tumour-suppressive networks in premalignant lesions. Here, we interrogate the relationship of DDR signalling to mutational accumulation in IM lesions.
1714. The study of Lynch syndrome in a special population reveals a strong founder effect and an unusual mutational mechanism in familial adenomatous polyposis.
作者: Abdul K Siraj.;Tariq Masoodi.;Rong Bu.;Sandeep Kumar Parvathareddy.;Sarah Siraj.;Ali Alassiri.;Fouad Al-Dayel.;Fowzan S Alkuraya.;Khawla S Al-Kuraya.
来源: Gut. 2020年69卷11期2048-2049页 1715. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
作者: Cyril Sobolewski.;Daniel Abegg.;Flavien Berthou.;Dobrochna Dolicka.;Nicolas Calo.;Christine Sempoux.;Margot Fournier.;Christine Maeder.;Anne-Sophie Ay.;Pierre-Alain Clavien.;Bostjan Humar.;Jean-François Dufour.;Alexander Adibekian.;Michelangelo Foti.
来源: Gut. 2020年69卷10期1841-1854页
Hepatocellular carcinoma (HCC) development occurs with non-alcoholic fatty liver disease (NAFLD) in the absence of cirrhosis and with an increasing incidence due to the obesity pandemic. Mutations of tumour suppressor (TS) genes and oncogenes (ONC) have been widely characterised in HCC. However, mounting evidence indicates that non-genomic alterations of TS/ONC occur early with NAFLD, thereby potentially promoting hepatocarcinogenesis in an inflammatory/fibrotic context. The aim of this study was to identify and characterise these alterations.
1717. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density.
作者: Peter Bossuyt.;Hiroshi Nakase.;Séverine Vermeire.;Gert de Hertogh.;Tom Eelbode.;Marc Ferrante.;Tadashi Hasegawa.;Hilde Willekens.;Yousuke Ikemoto.;Takao Makino.;Raf Bisschops.
来源: Gut. 2020年69卷10期1778-1786页
The objective evaluation of endoscopic disease activity is key in ulcerative colitis (UC). A composite of endoscopic and histological factors is the goal in UC treatment. We aimed to develop an operator-independent computer-based tool to determine UC activity based on endoscopic images.
1719. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
作者: Sho Suzuki.;Takuji Gotoda.;Chika Kusano.;Hisatomo Ikehara.;Ryoji Ichijima.;Motoki Ohyauchi.;Hirotaka Ito.;Masashi Kawamura.;Yohei Ogata.;Masahiko Ohtaka.;Moriyasu Nakahara.;Koichi Kawabe.
来源: Gut. 2020年69卷6期1019-1026页
To date, no randomised trials have compared the efficacy of vonoprazan and amoxicillin dual therapy with other standard regimens for Helicobacter pylori treatment. This study aimed to investigate the efficacy of the 7-day vonoprazan and low-dose amoxicillin dual therapy as a first-line H. pylori treatment, and compared this with vonoprazan-based triple therapy.
1720. The epidemiology of hepatitis delta virus infection in Cameroon.
作者: Camille Besombes.;Richard Njouom.;Juliette Paireau.;Guillaume Lachenal.;Gaëtan Texier.;Mathurin Tejiokem.;Simon Cauchemez.;Jacques Pépin.;Arnaud Fontanet.
来源: Gut. 2020年69卷7期1294-1300页
To investigate the distribution and risk factors of hepatitis delta virus (HDV) infection in Cameroon.
|